Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.

Publication date: Jul 11, 2023

In the situation of mass vaccination against COVID-19, few studies have reported on the early kinetics of specific antibodies (IgG/IgM/IgA) of vaccine breakthrough cases. There is still a lack of epidemiological evidence about the value of serological indicators in the auxiliary diagnosis of COVID-19 infection, especially when the nucleic acid results were undetectable. Omicron breakthrough cases post-inactivated vaccination (n = 456) and COVID-19-naive individuals with two doses of inactivated vaccination (n = 693) were enrolled. Blood samples were collected and tested for SARS-CoV-2 antibody levels based on the magnetic chemiluminescence enzyme immunoassay. Among Omicron breakthrough cases, the serum IgG antibody level was 36. 34 Sample/CutOff (S/CO) (95% confidence interval [CI], 31. 89 to 40. 79) in the acute phase and 88. 45 S/CO (95% CI, 82. 79 to 94. 12) in the recovery phase. Serum IgA can be detected in the first week post-symptom onset (PSO) and showed an almost linear increase within 5 weeks PSO. Compared with those of breakthrough cases, IgG and IgA titers of the postimmune group were much lower (4. 70 S/CO and 0. 46 S/CO, respectively). Multivariate regression showed that serum IgG and IgA levels in Omicron breakthrough cases were mainly affected by the weeks PSO (P 

Concepts Keywords
5weeks early kinetics
Antibodies Omicron breakthrough infection
Covid SARS-CoV-2
Inactivated specific antibodies
Postimmune vaccinated


Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO vaccine
disease VO LACK
disease MESH infection
disease IDO blood
disease IDO symptom
disease MESH breakthrough infection
disease VO vaccinated

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *